Recent Articles in News & Analysis

New Jersey’s Navigator Medicines raised $100 million in an initial funding to develop an OX40L-targeted portfolio that was in-licensed from Korea’s IMBiologics. RA Capital Management and Forbion, a Dutch life sciences investor, formed Navigator and initiated the agreement with IMBiologics earlier this year, signing a $995 million agreement for global rights (ex-Asia) to the immune disease candidates. Last week, IMBiologics out-licensed China rights for the dual targeting molecule to Hangzhou’s Huadong Pharmaceutical in a $383 million agreement. IMBiologics is currently conducting a Phase I trial of the candidate in the US among healthy volunteers. More details....

Share this with colleagues:  

Shanghai’s YolTech Therapeutics sold China rights for its PCSK9-targeting base editing therapeutic to Shenzhen Salubris Pharma in a $145 million agreement. YOLT-101 is a single-course, in vivo, liver base editing medicine that is designed to permanently inhibit the PCSK9 gene in the liver to reduce disease-driving LDL-C. The candidate is currently being evaluated in several China investigator led trials. YolTech will continue preclinical development of YOLT-101, while Salubris will be responsible for clinical trials in Mainland China. YolTech will receive $30 million upfront and up to $115 million in milestones, plus tiered royalties. More details....

Share this with colleagues:  

Shanghai DualityBio plans to conduct a Hong Kong IPO to support its portfolio of ADC therapeutics for cancer and autoimmune diseases. Founded in 2019, DualityBio has built an innovative and differentiated pipeline of 12 ADC candidates, discovered in-house. These include six clinical-stage ADCs aimed at indications with unmet medical needs, two next-generation bispecific ADCs (BsADCs) and one autoimmune ADC planned for clinical trials over the next two years. The company has forged partnerships with BioNTech SE, BeiGene, Ltd. and Adcendo ApS with a total deal value of more than $4.0 billion. More details....

Share this with colleagues:  

GenFleet Therapeutics was approved for a China launch of Dupert (fulzerasib),a KRAS G12C inhibitor, as a second-line treatment for advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. Patients must have previously had at least one systemic therapy. About 85% of all lung cancers are NSCLC, and KRAS is the most frequently mutated driver gene in NSCLC. The approve is a first in China for a KRAS G12C inhibitor. In 2021, GenFleet out-licensed greater China commercialization rights for fulzerasib to Suzhou’s Innovent in a deal worth up to $315 million. More details...

Share this with colleagues: